JP2015143283A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015143283A5 JP2015143283A5 JP2015098562A JP2015098562A JP2015143283A5 JP 2015143283 A5 JP2015143283 A5 JP 2015143283A5 JP 2015098562 A JP2015098562 A JP 2015098562A JP 2015098562 A JP2015098562 A JP 2015098562A JP 2015143283 A5 JP2015143283 A5 JP 2015143283A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- ring
- hydrogen bond
- aromatic ring
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000004429 atoms Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 102100019218 MEN1 Human genes 0.000 claims 1
- 101700045140 MEN1 Proteins 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 125000004434 sulfur atoms Chemical group 0.000 claims 1
Claims (5)
- 次式で表わされる構造を有する化合物または該化合物の薬学的に許容可能な塩：
- 上記構造が化合物３２〜４１および８４〜８６から選択される、請求項１に記載の化合物または該化合物の薬学的に許容可能な塩。
- 請求項１または２に記載の化合物または該化合物の薬学的に許容可能な塩を含有する、薬剤。
- 白血病を治療するための、請求項３に記載の薬剤。
- 請求項１に記載の化合物または該化合物の薬学的に許容可能な塩の、ＭＬＬとメニンとの相互作用を阻害するための組成物の調製における、使用。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24010209P | 2009-09-04 | 2009-09-04 | |
| US61/240,102 | 2009-09-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528106A Division JP5792171B2 (ja) | 2009-09-04 | 2010-09-03 | 白血病を治療するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015143283A JP2015143283A (ja) | 2015-08-06 |
| JP2015143283A5 true JP2015143283A5 (ja) | 2015-09-17 |
Family
ID=43649670
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528106A Active JP5792171B2 (ja) | 2009-09-04 | 2010-09-03 | 白血病を治療するための組成物および方法 |
| JP2015098562A Pending JP2015143283A (ja) | 2009-09-04 | 2015-05-13 | 白血病を治療するための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528106A Active JP5792171B2 (ja) | 2009-09-04 | 2010-09-03 | 白血病を治療するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8993552B2 (ja) |
| EP (1) | EP2473054B1 (ja) |
| JP (2) | JP5792171B2 (ja) |
| CN (1) | CN102984941B (ja) |
| AU (2) | AU2010289321A1 (ja) |
| CA (1) | CA2773131C (ja) |
| WO (1) | WO2011029054A1 (ja) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2747703C (en) | 2009-01-06 | 2021-06-15 | Curemark Llc | Compositions and methods for the treatment or the prevention of infections by e. coli |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| HUE032983T2 (en) | 2009-09-03 | 2017-11-28 | Bristol Myers Squibb Co | Quinazoline as potassium ion channel inhibitor |
| US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
| US8703941B2 (en) | 2011-01-10 | 2014-04-22 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
| GB201114212D0 (en) * | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| WO2013068592A1 (en) * | 2011-11-10 | 2013-05-16 | Fondation Jerome Lejeune | Inhibitors of cystathionine beta synthase to reduce the neurotoxic overproduction of endogenous hydrogen sulfide |
| AR090037A1 (es) | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
| AU2013207972B2 (en) * | 2012-01-10 | 2017-06-15 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
| EP2806875B1 (en) * | 2012-01-25 | 2017-07-19 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating compounds |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| EP2671575A1 (en) * | 2012-06-04 | 2013-12-11 | Universität Regensburg | Ras inhibitors |
| ES2675314T3 (es) | 2012-06-11 | 2018-07-10 | Bristol-Myers Squibb Company | Profármacos de ácido fosforamídico de 5-[5-fenil-4-(piridin-2-ilmetilamino) quinazolin-2-il] piridin-3-sulfonamida |
| WO2014011902A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| IN2015DN00127A (ja) | 2012-07-11 | 2015-05-29 | Nimbus Iris Inc | |
| MX2015002887A (es) | 2012-09-06 | 2015-07-06 | Plexxikon Inc | Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello. |
| CA2886495C (en) * | 2012-09-28 | 2023-09-19 | Ignyta, Inc. | Azaquinazoline inhibitors of atypical protein kinase c |
| GB201217704D0 (en) | 2012-10-03 | 2012-11-14 | Ucb Pharma Sa | Therapeutic agents |
| US20140136295A1 (en) | 2012-11-13 | 2014-05-15 | Apptio, Inc. | Dynamic recommendations taken over time for reservations of information technology resources |
| US9175007B2 (en) | 2013-01-10 | 2015-11-03 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
| WO2014127191A1 (en) | 2013-02-15 | 2014-08-21 | The Regents Of The University Of Michigan | Compositions and methods relating to hindering dot1l recruitment by mll-fusion proteins |
| AU2014249233A1 (en) | 2013-03-13 | 2015-09-24 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| CN104119343A (zh) * | 2013-04-25 | 2014-10-29 | 苏州科捷生物医药有限公司 | 2-三氟甲基噻二唑类化合物及其用途 |
| MX2016003843A (es) | 2013-09-27 | 2017-02-15 | Nimbus Iris Inc | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. |
| TWI648281B (zh) * | 2013-10-17 | 2019-01-21 | 日商安斯泰來製藥股份有限公司 | 含硫二環式化合物 |
| JP2017001954A (ja) * | 2013-11-08 | 2017-01-05 | 石原産業株式会社 | 含窒素飽和複素環化合物 |
| CN104892589A (zh) | 2014-03-07 | 2015-09-09 | 中国科学院上海药物研究所 | 一类杂环化合物、其制备方法和用途 |
| MX2016011675A (es) * | 2014-03-11 | 2016-12-14 | Godavari Biorefineries Ltd | Compuestos dirigidos a las celulas madre de cancer. |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| US10526341B2 (en) | 2014-11-19 | 2020-01-07 | Memorial Sloan-Kettering Cancer Center | Thienopyrimidines and uses thereof |
| CN104592248A (zh) * | 2014-12-31 | 2015-05-06 | 芜湖杨燕制药有限公司 | 一种4-氯-6-取代噻吩并[2,3-d]嘧啶化合物的制备方法 |
| WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| AR104020A1 (es) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| AU2017212572A1 (en) | 2016-01-26 | 2018-08-23 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| WO2017161028A1 (en) * | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| KR102419524B1 (ko) * | 2016-03-16 | 2022-07-08 | 쿠라 온콜로지, 인크. | 메닌-mll의 가교된 이환식 억제제 및 사용 방법 |
| KR20190015275A (ko) | 2016-05-02 | 2019-02-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 메닌 억제제로서의 피페리딘 |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| ES2966316T3 (es) | 2016-09-14 | 2024-04-19 | Janssen Pharmaceutica Nv | Inhibidores bicíclicos fusionados de interacción de MENIN-MLL |
| MX2019002962A (es) | 2016-09-14 | 2019-07-04 | Janssen Pharmaceutica Nv | Inhibidores espirobiciclicos de la interaccion de menina-mll. |
| WO2018050686A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| SG11201903483VA (en) | 2016-10-28 | 2019-05-30 | Icahn School Med Mount Sinai | Compositions and methods for treating ezh2-mediated cancer |
| AU2017370694A1 (en) | 2016-12-08 | 2019-07-25 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
| AU2017376599B2 (en) * | 2016-12-15 | 2021-10-07 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-MLL interaction |
| WO2018109088A1 (en) | 2016-12-15 | 2018-06-21 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-mll interaction |
| EA038388B1 (ru) * | 2017-01-16 | 2021-08-19 | Кура Онколоджи, Инк. | Замещенные ингибиторы менина-mll и способы применения |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| CA3058448A1 (en) | 2017-03-31 | 2018-10-04 | The Regents Of The University Of Michigan | Piperidines as covalent menin inhibitors |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| WO2019060365A1 (en) | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| WO2019173516A1 (en) | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
| CN112105621B (zh) | 2018-03-30 | 2024-02-20 | 住友制药株式会社 | 光学活性桥型环状仲胺衍生物 |
| AU2019351820A1 (en) | 2018-10-03 | 2021-03-04 | Agios Pharmaceuticals, Inc. | Small molecule menin inhibitors |
| CN112574224A (zh) * | 2019-09-30 | 2021-03-30 | 上海迪诺医药科技有限公司 | Kras g12c抑制剂及其应用 |
| WO2021067215A1 (en) | 2019-09-30 | 2021-04-08 | Agios Pharmaceuticals, Inc. | Piperidine compounds as menin inhibitors |
| CN111297863B (zh) * | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用 |
| WO2021207310A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
| TW202204333A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
| WO2022086937A1 (en) * | 2020-10-21 | 2022-04-28 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional compounds as degraders of enl |
| EP4334320A1 (en) | 2021-05-08 | 2024-03-13 | JANSSEN Pharmaceutica NV | Substituted spiro derivatives |
| JP2024518434A (ja) | 2021-05-08 | 2024-05-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換スピロ誘導体 |
| AU2022286467A1 (en) | 2021-06-01 | 2024-01-25 | Janssen Pharmaceutica Nv | SUBSTITUTED PHENYL-1H-PYRROLO[2, 3-c]PYRIDINE DERIVATIVES |
| EP4347600A1 (en) | 2021-06-03 | 2024-04-10 | JANSSEN Pharmaceutica NV | Pyridazines or 1,2,4-triazines substituted by spirocyclic amines |
| KR20240021808A (ko) | 2021-06-17 | 2024-02-19 | 얀센 파마슈티카 엔브이 | 암과 같은 질환의 치료를 위한 (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드 베실레이트 염 |
| WO2023056589A1 (en) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Menin inhibitors and methods of use for treating cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10330377A (ja) * | 1997-06-02 | 1998-12-15 | Kyowa Hakko Kogyo Co Ltd | ピペリジン誘導体 |
| PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| EP1382603B1 (en) | 2001-04-26 | 2008-07-23 | Eisai R&D Management Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
| JP2005503345A (ja) | 2001-04-30 | 2005-02-03 | バイエル・コーポレーシヨン | 新規な４−アミノ−５，６−置換チオフェノ［２，３−ｄ］ピリミジン |
| US7115741B2 (en) * | 2001-09-06 | 2006-10-03 | Levy Daniel E | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds |
| WO2004030672A1 (en) | 2002-10-02 | 2004-04-15 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
| AU2003258662A1 (en) * | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4-amino-quinazolines as anti cancer agents |
| WO2005020897A2 (en) * | 2003-08-22 | 2005-03-10 | Dendreon Corporation | Compositions and methods for the treatment of disease associated with trp-p8 expression |
| US20050123906A1 (en) | 2003-11-06 | 2005-06-09 | Rana Tariq M. | Protein modulation |
| AU2005269974A1 (en) | 2004-07-06 | 2006-02-09 | Angion Biomedica Corporation | Quinazoline modulators of hepatocyte growth factor / c-Met activity for the treatment of cancer |
| US20060281769A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators |
| US20060281771A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
| KR20080040032A (ko) * | 2005-09-02 | 2008-05-07 | 티보텍 파마슈티칼즈 리미티드 | Ｈｃｖ 저해제로서의 벤조디아제핀 |
| KR20090047391A (ko) * | 2006-04-07 | 2009-05-12 | 데벨로겐 악틴게젤샤프트 | 약제학적 조성물을 위한 Ｍｎｋ1/Ｍｎｋ2 억제 활성을 갖는티에노피리미딘 |
| WO2008099019A1 (en) * | 2007-02-16 | 2008-08-21 | Tibotec Pharmaceuticals Ltd. | 6-hydroxy-dibenzodiazepinones useful as hepatitis c virus inhibitors |
| FR2913017A1 (fr) | 2007-02-23 | 2008-08-29 | Cerep Sa | Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire |
| DE602008004649D1 (de) * | 2007-03-19 | 2011-03-03 | Council Scient Ind Res | Anthranilsäure-derivat als antikrebswirkstoff und verfahren zur herstellung davon |
| US20080293699A1 (en) | 2007-05-25 | 2008-11-27 | Burnham Institute For Medical Research | Inhibitors of thapsigargin-induced cell death |
| WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| WO2009064388A2 (en) | 2007-11-09 | 2009-05-22 | Liu Jun O | Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| AU2009291783A1 (en) * | 2008-09-10 | 2010-03-18 | Alcon Research, Ltd | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
| WO2011003418A1 (en) * | 2009-07-08 | 2011-01-13 | Leo Pharma A/S | Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors |
-
2010
- 2010-09-03 AU AU2010289321A patent/AU2010289321A1/en not_active Abandoned
- 2010-09-03 CN CN201080050708.8A patent/CN102984941B/zh active Active
- 2010-09-03 US US12/875,968 patent/US8993552B2/en active Active
- 2010-09-03 JP JP2012528106A patent/JP5792171B2/ja active Active
- 2010-09-03 CA CA2773131A patent/CA2773131C/en active Active
- 2010-09-03 WO PCT/US2010/047894 patent/WO2011029054A1/en active Application Filing
- 2010-09-03 EP EP10814591.3A patent/EP2473054B1/en active Active
-
2014
- 2014-06-27 AU AU2014203516A patent/AU2014203516B2/en active Active
-
2015
- 2015-03-23 US US14/665,600 patent/US20160045504A1/en not_active Abandoned
- 2015-05-13 JP JP2015098562A patent/JP2015143283A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015143283A5 (ja) | ||
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| JP2017537940A5 (ja) | ||
| JP2016518437A5 (ja) | ||
| JP2016540742A5 (ja) | ||
| JP2019524883A5 (ja) | ||
| JP2018511647A5 (ja) | ||
| JP2017509689A5 (ja) | ||
| JP2016503797A5 (ja) | ||
| PE20140608A1 (es) | Analogos de nucleotidos sustituidos | |
| JP2010504286A5 (ja) | ||
| JP2015531773A5 (ja) | ||
| JP2016537382A5 (ja) | ||
| JP2016515561A5 (ja) | ||
| JP2014525420A5 (ja) | ||
| JP2013510178A5 (ja) | ||
| JP2014513051A5 (ja) | ||
| JP2014526533A5 (ja) | ||
| JP2013509392A5 (ja) | ||
| JP2016505637A5 (ja) | ||
| JP2016531126A5 (ja) | ||
| JP2016528273A5 (ja) | ||
| JP2015063518A5 (ja) | 有機化合物 | |
| RU2016118399A (ru) | Производные 4-аминометилбензойной кислоты | |
| JP2014510147A5 (ja) |